All In Biotech

Drug Trial Radar · NCT04294160

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

122

Actual

Start

Jul 22, 2020

Primary completion

Sep 25, 2024

Study completion Sep 25, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

Conditions

  • BRAF V600 Colorectal Cancer

Interventions

  • DabrafenibDrug

    Capsule for oral use

  • LTT462Drug

    Capsule for oral use

  • TrametinibDrug

    Tablet for oral use

  • LXH254Drug

    Tablet for oral use

  • TNO155Drug

    Capsule for oral use

  • SpartalizumabBiological

    Liquid in vial (Concentrate for solution for infusion) for intravenous use

  • TislelizumabBiological

    Liquid in vial (Concentrate for solution for infusion) for intravenous use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and nature of dose limiting toxicities (DLTs) in the first cycleTime frame: 30 months
  2. Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, and ECGsTime frame: 34 months
  3. Frequency of dose interruptionsTime frame: 30 months
  4. Frequency of dose reductionsTime frame: 30 months
  5. Dose intensityTime frame: 30 months

Locations

18 sites in 10 countries. Site status is shown where the registry gives one.

  • University of California LA Santa Monica Location

    Los Angeles, California

  • Massachusetts General Hospital Massachusetts General Hospital

    Boston, Massachusetts

  • Sarah Cannon Research Institute SC

    Nashville, Tennessee

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Tel Aviv, Israel

  • Novartis Investigative Site

    Zoetermeer, Netherlands

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Valencia, Valencia, Spain

  • Novartis Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.